---
schema_version: "secwatch.filing_event.v1"
accession: "0001567264-26-000047"
form_type: "8-K"
ticker: "INTS"
cik: "0001567264"
company_name: "INTENSITY THERAPEUTICS, INC."
filed_at: "2026-05-07T23:59:59+00:00"
generated_at: "2026-05-14T21:40:55.694136+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Intensity Therapeutics Q1 net loss $2.4M; cash $10.2M; resumes trial enrollment

## Summary
- Net loss $2.4M for Q1 2026 vs $3.3M in Q1 2025; R&D expenses fell to $1.2M from $2.2M.
- Cash and equivalents $10.2M at March 31, 2026; $60M ATM facility established in March 2026.
- Phase 2 INVINCIBLE-4 TNBC study: 71.4% pCR in INT230-6+SOC arm vs 33% in SOC alone; 44% fewer grade 3+ AEs.
- Swissmedic approved resumption of INVINCIBLE-4 enrollment; plan to resume Q2 2026 and start France sites.
- Decision to resume limited U.S. enrollment in Phase 3 INVINCIBLE-3 soft tissue sarcoma study by Q3 2026.

## SEC filing metadata
- accession: 0001567264-26-000047
- form_type: 8-K
- ticker: INTS
- cik: 0001567264
- company_name: INTENSITY THERAPEUTICS, INC.
- filed_at: 2026-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1567264/000156726426000047/0001567264-26-000047-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1567264/000156726426000047/intensity-20260507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001567264-26-000047
- JSON: https://secwatch.observer/filing/0001567264-26-000047.json
- Plain text: https://secwatch.observer/filing/0001567264-26-000047.txt

## Source-grounded claims
- claim_id: 18fdd06c2086385cb26fe89b743e8add6edcab7d
  claim: INTENSITY THERAPEUTICS, INC. reported the three months ended March 31, 2026 results: net income net loss was $2.4 million.
  evidence_excerpt: 31, 2025. This increase was partially offset by lower stock-based compensation and one-time expenses related to our reverse stock split in February 2026. Overall, net loss was $2.4 million for the three months ended March 31, 2026, compared to a net loss of $3.3 million for the three months ended March 31, 2025. As of March 31, 2026, cash and cash equivalents
  evidence_url: https://www.sec.gov/Archives/edgar/data/1567264/000156726426000047/0001567264-26-000047-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.